Last reviewed · How we verify

Postpartum Antibiotics

Washington University School of Medicine · FDA-approved active Small molecule Quality 5/100

Postpartum Antibiotics is a Small molecule drug developed by Washington University School of Medicine. It is currently FDA-approved.

Postpartum Antibiotics, developed by Washington University School of Medicine, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent until 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic namePostpartum Antibiotics
SponsorWashington University School of Medicine
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Postpartum Antibiotics

What is Postpartum Antibiotics?

Postpartum Antibiotics is a Small molecule drug developed by Washington University School of Medicine.

Who makes Postpartum Antibiotics?

Postpartum Antibiotics is developed and marketed by Washington University School of Medicine (see full Washington University School of Medicine pipeline at /company/washington-university-school-of-medicine).

What development phase is Postpartum Antibiotics in?

Postpartum Antibiotics is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing